Oncotype DX cancer testing (ordering period 3)

Ended Awarded Last action

Contract number
FA486123F0082
Awardee
Awarding agency
Obligated
$124,589

Award facts

Contract value 100% obligated
$124,588.79 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
621511 Medical Laboratories
PSC
Q999 Medical- Other
Set-aside
No set-aside
Competition
Not Competed Only One Source
Pricing
Firm Fixed Price
Place of performance
North Las Vegas, NV 89030, USA

Award details come from SAM.gov/FPDS.

About this award

The Department of the Air Force Air Combat Command awarded a $124,588.79 firm fixed price delivery order to Genomic Health, Inc. for Oncotype DX cancer testing services during the ordering period from March 2023 through March 2024. Genomic Health is a subsidiary of Exact Sciences Corporation which will perform the testing through its laboratory services division Exact Sciences Laboratories. The delivery order was awarded without a set-aside designation to support the Air Force's cancer screening and treatment programs through provision of Oncotype DX genomic tests that analyze gene expression to determine the likelihood of disease recurrence and predict which patients are most likely to benefit from chemotherapy.

Quick answers

Who was awarded contract FA486123F0082?

FA486123F0082 was awarded to Genomic Health, Inc. by Air Combat Command (Air Force) on March 16, 2023.

How much is contract FA486123F0082 worth?

The government has obligated $124,589 on FA486123F0082.

Is contract FA486123F0082 an order under another contract?

Yes. FA486123F0082 is a delivery order under FA486121D0004, an indefinite delivery contract.

Was contract FA486123F0082 competed?

The extent of competition for FA486123F0082 was not competed.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award